At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,511 enrolled
Drug / intervention
20-valent pneumococcal conjugate vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
In Brief
A Phase 3 clinical trial evaluating 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine for Pneumococcal Disease. Completed, enrolled 1,511 participants across 97 sites in 11 countries.
Detailed Summary
This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesArgentina, Canada, Chile, Czechia, Finland, Germany, Greece, Hungary, Puerto Rico, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartMay 2020
Primary CompletionAug 2022
TodayJul 2026
First PostedMay 7, 2020
Enrollment StartMay 21, 2020
Primary CompletionAug 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.2 years ago
Interventions
20-valent pneumococcal conjugate vaccinebiological
Pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccinebiological
Pneumococcal conjugate vaccine